Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

Christian Pfister(Inserm), Stéphane Culine(Hôpital Saint-Louis), Brigitte Laguerre(Centre Eugène Marquis), Valentin Harter, Aude Fléchon(Institut Català d'Ornitologia), Gwénaëlle Gravis(Centre National de la Recherche Scientifique), Nicolas Mottet, M. Soulié(Hôpital Rangueil), Yves Allory(Institut Curie), Laurent Guy, Florence Joly(Centre François Baclesse)
European Urology
August 28, 2020
10.1016/j.eururo.2020.08.024
Cited by 246

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Historical Climatology In Europe – The State Of The Art
|Climatic Change|2005|656
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
|Journal of Clinical Oncology|2021|530